SCHEDULE 13G/A: BlackRock Amends Stake in ADMA Biologics, Reports 15.1% Passive Ownership

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 15.1% beneficial ownership stake in ADMA Biologics, Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 35,907,601 shares of ADMA Biologics, Inc. common stock.
• This ownership represents 15.1% of the total outstanding common stock of ADMA Biologics, Inc.
• BlackRock holds sole voting power over 35,639,421 shares and sole dispositive power over 35,907,601 shares.
• The filing is an Amendment No. 3 to a Schedule 13G, indicating an update to previously reported ownership.
• The shares are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of ADMA Biologics, Inc.
• One specific BlackRock entity, iShares Core S&P Small-Cap ETF, is noted to hold more than 5% of the common stock of ADMA Biologics, Inc.

Sentiment

Score: 7

Explanation: The filing indicates a significant passive stake by a major institutional investor, BlackRock, which can be seen as a positive signal of confidence in ADMA Biologics. There are no negative disclosures within the filing itself.

Positives

• A major institutional investor, BlackRock, Inc., holds a significant 15.1% stake, which can be viewed as a vote of confidence in ADMA Biologics.
• The ownership is passive, indicating BlackRock is not seeking to influence control, which can provide stability and reduce the likelihood of activist-driven disruptions.

Risks

• The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, mitigating a potential risk of activist investor intervention.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding ADMA Biologics, Inc.'s future performance or outlook, as it primarily reports current ownership by an institutional investor.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (BlackRock, Inc. certification)

Industry Context

This filing reflects a significant passive investment by one of the world's largest asset managers, BlackRock, in a biologics company. Such institutional holdings are common across various industries, including the healthcare and biotechnology sectors, where large funds often take substantial positions in publicly traded companies as part of their diversified portfolios.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a regulatory requirement for investors acquiring more than 5% of a company's stock with a passive intent.
• BlackRock's 15.1% stake in ADMA Biologics is a substantial institutional holding, comparable to other large asset managers' significant passive stakes in small-cap companies within their respective investment portfolios, such as Vanguard's holdings in various biotech firms or State Street's positions in pharmaceutical companies.
• The filing itself does not provide performance metrics for direct comparison to industry peers, focusing solely on ownership disclosure.

Stakeholder Impact

• Shareholders: BlackRock's significant passive stake may instill confidence and potentially attract other institutional investors, positively impacting share price stability and liquidity.
• Management: The passive nature of the investment suggests no immediate pressure for strategic or operational changes from this shareholder.

Next Steps

• BlackRock, Inc. will continue to monitor its beneficial ownership in ADMA Biologics, Inc.
• Further Schedule 13G amendments will be filed if there are material changes to BlackRock's ownership percentage (e.g., an increase or decrease of 1% or more).

Key Dates

Keywords

ADMA Biologics, BlackRock, Schedule 13G, Institutional Ownership, Common Stock, Beneficial Ownership, Passive Investment, SEC Filing, Investment Management, Biologics